JP2022521119A5 - - Google Patents

Info

Publication number
JP2022521119A5
JP2022521119A5 JP2021532911A JP2021532911A JP2022521119A5 JP 2022521119 A5 JP2022521119 A5 JP 2022521119A5 JP 2021532911 A JP2021532911 A JP 2021532911A JP 2021532911 A JP2021532911 A JP 2021532911A JP 2022521119 A5 JP2022521119 A5 JP 2022521119A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
formula
administered
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/ES2020/070070 external-priority patent/WO2020157362A1/en
Publication of JP2022521119A publication Critical patent/JP2022521119A/ja
Publication of JP2022521119A5 publication Critical patent/JP2022521119A5/ja
Priority to JP2024158993A priority Critical patent/JP2024175025A/ja
Pending legal-status Critical Current

Links

JP2021532911A 2019-01-30 2020-01-30 組織の灌流の増加における使用のためのイノシトールリン酸化合物 Pending JP2022521119A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158993A JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
EP19382061.0 2019-01-30
US201962913259P 2019-10-10 2019-10-10
US62/913,259 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158993A Division JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Publications (2)

Publication Number Publication Date
JP2022521119A JP2022521119A (ja) 2022-04-06
JP2022521119A5 true JP2022521119A5 (cg-RX-API-DMAC7.html) 2022-09-14

Family

ID=69770927

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532911A Pending JP2022521119A (ja) 2019-01-30 2020-01-30 組織の灌流の増加における使用のためのイノシトールリン酸化合物
JP2024158993A Pending JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158993A Pending JP2024175025A (ja) 2019-01-30 2024-09-13 組織の灌流の増加における使用のためのイノシトールリン酸化合物

Country Status (11)

Country Link
US (2) US20220000889A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917535A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022521119A (cg-RX-API-DMAC7.html)
KR (1) KR20210148078A (cg-RX-API-DMAC7.html)
CN (1) CN113365636A (cg-RX-API-DMAC7.html)
AU (1) AU2020213713B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014897A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130735A1 (cg-RX-API-DMAC7.html)
IL (1) IL285084A (cg-RX-API-DMAC7.html)
MX (1) MX2021008966A (cg-RX-API-DMAC7.html)
WO (1) WO2020157362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003653A (es) 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
AU2021380963A1 (en) * 2020-11-20 2023-06-22 ETH Zürich Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
AU6912500A (en) * 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
MX347723B (es) 2011-09-29 2017-05-10 Eth Zuerich Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
ES2762984T3 (es) 2015-12-11 2020-05-26 Eth Zuerich 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile
SMT202100406T1 (it) * 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica

Similar Documents

Publication Publication Date Title
JP2020189864A5 (cg-RX-API-DMAC7.html)
JP2023500020A5 (cg-RX-API-DMAC7.html)
JP2020007350A5 (cg-RX-API-DMAC7.html)
JP2007500229A5 (cg-RX-API-DMAC7.html)
JP2012529483A5 (cg-RX-API-DMAC7.html)
JP2020075939A5 (cg-RX-API-DMAC7.html)
JP2024503723A5 (cg-RX-API-DMAC7.html)
JP2005506294A (ja) テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形
CA2906196A1 (en) Enantiomerically enriched s-oxprenolol compositions for treating cancer
RU2002101622A (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
JP2025148449A5 (cg-RX-API-DMAC7.html)
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
WO2007069727A1 (ja) 急性腎不全の予防または治療剤
CA2593171A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
TW202038931A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
RU2021125195A (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
JPH0624989A (ja) 抗−アテローム性動脈硬化薬としてのドキサゾシンのヒドロキシル化代謝産物および誘導体
RU2259827C2 (ru) Лечение или предупреждение гипотензии и шока
EP0717625B1 (en) A method of treating liver disease and like indications with vasodilating agents
JPH01156916A (ja) 肝疾患治療剤
JP4253371B2 (ja) 筋クランプ治療剤
CN1501802A (zh) 芳基乙烯磺酰胺衍生物的新用途
RU2021129954A (ru) Циклические фосфатные соединения
JP2004231557A (ja) エピネフリン含有抗腫瘍剤